nach oben

Erschienen in:

07.05.2018 | Original Article

Metastatic breast cancer patients’ expectations and priorities for symptom improvement

verfasst von: Danielle B. Tometich, Catherine E. Mosher, Adam T. Hirsh, Kevin L. Rand, Shelley A. Johns, Marianne S. Matthias, Samantha D. Outcalt, Bryan P. Schneider, Lida Mina, Anna Maria V. Storniolo, Erin V. Newton, Kathy D. Miller

Erschienen in: Supportive Care in Cancer | Ausgabe 11/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Little research has examined cancer patients’ expectations, goals, and priorities for symptom improvement. Thus, we examined these outcomes in metastatic breast cancer patients to provide patients’ perspectives on clinically meaningful symptom improvement and priorities for symptom management.

Methods

Eighty women with metastatic breast cancer participated in a survey with measures of comorbidity, functional status, engagement in roles and activities, distress, quality of life, and the modified Patient-Centered Outcomes Questionnaire that focused on 10 common symptoms in cancer patients.

Results

On average, patients reported low to moderate severity across the 10 symptoms and expected symptom treatment to be successful. Patients indicated that a 49% reduction in fatigue, 48% reduction in thinking problems, and 43% reduction in sleep problems would represent successful symptom treatment. Cluster analysis based on ratings of the importance of symptom improvement yielded three clusters of patients: (1) those who rated thinking problems, sleep problems, and fatigue as highly important, (2) those who rated pain as moderately important, and (3) those who rated all symptoms as highly important. The first patient cluster differed from other subgroups in severity of thinking problems and education.

Conclusions

Metastatic breast cancer patients report differing symptom treatment priorities and criteria for treatment success across symptoms. Considering cancer patients’ perspectives on clinically meaningful symptom improvement and priorities for symptom management will ensure that treatment is consistent with their values and goals.

Nur mit Berechtigung zugänglich

Ahmed S, Berzon RA, Revicki DA, Lenderking WR, Moinpour CM, Basch E, Reeve BB, Wu AW, International Society for Quality of Life Research (2012) The use of patient-reported outcomes (PRO) within comparative effectiveness research: implications for clinical practice and health care policy. Med Care 50:1060–1070. https://doi.org/10.1097/MLR.0b013e318268aaff CrossRefPubMed

Kent EE, Malinoff R, Rozjabek HM, Ambs A, Clauser SB, Topor MA, Yuan G, Burroughs J, Rodgers AB, DeMichele K (2016) Revisiting the surveillance epidemiology and end results cancer registry and medicare health outcomes survey (SEER-MHOS) linked data resource for patient-reported outcomes research in older adults with cancer. J Am Geriatr Soc 64:186–192. https://doi.org/10.1111/jgs.13888 CrossRefPubMed

Reeve BB, Mitchell SA, Dueck AC et al (2014) Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials. J Natl Cancer Inst 106:1–8. https://doi.org/10.1093/jnci/dju129 CrossRef

Epstein RM, Fiscella K, Lesser CS, Stange KC (2010) Why the nation needs a policy push on patient-centered health care. Health Aff 29:1489–1495. https://doi.org/10.1377/hlthaff.2009.0888 CrossRef

McMillan SS, Kendall E, Sav A et al (2013) Patient-centered approaches to health care: a systematic review of randomized controlled trials. Med Care Res Rev 70:567–596. https://doi.org/10.1177/1077558713496318 CrossRefPubMed

Rao JK, Anderson LA, Inui TS, Frankel RM (2007) Communication interventions make a difference in conversations between physicians and patients: a systematic review of the evidence. Med Care 45:340–349. https://doi.org/10.1097/01.mlr.0000254516.04961.d5 CrossRefPubMed

Joosten EA, DeFuentes-Merillas L, De Weert G et al (2008) Systematic review of the effects of shared decision-making on patient satisfaction, treatment adherence and health status. Psychother Psychosom 77:219–226. https://doi.org/10.1159/000126073 CrossRefPubMed

Te Boveldt N, Vernooij-Dassen M, Leppink I et al (2014) Patient empowerment in cancer pain management: an integrative literature review. Psychooncology 23:1203–1211. https://doi.org/10.1002/pon.3573 CrossRef

Brown JL, Edwards PS, Atchison JW, Lafayette-Lucey A, Wittmer VT, Robinson ME (2008) Defining patient-centered, multidimensional success criteria for treatment of chronic spine pain. Pain Med 9:851–862. https://doi.org/10.1111/j.1526-4637.2007.00357.x CrossRefPubMed

10.

Nisenzon AN, Robinson ME, Bowers D, Banou E, Malaty I, Okun MS (2011) Measurement of patient-centered outcomes in Parkinson’s disease: what do patients really want from their treatment? Parkinsonism Relat Disord 17:89–94. https://doi.org/10.1016/j.parkreldis.2010.09.005 CrossRefPubMed

11.

O'Brien EM, Staud RM, Hassinger AD, McCulloch RC, Craggs JG, Atchison JW, Price DD, Robinson ME (2010) Patient-centered perspective on treatment outcomes in chronic pain. Pain Med 11:6–15. https://doi.org/10.1111/j.1526-4637.2009.00685.x CrossRefPubMed

12.

Robinson ME, Brown JL, George SZ, Edwards PS, Atchison JW, Hirsh AT, Waxenberg LB, Wittmer V, Fillingim RB (2005) Multidimensional success criteria and expectations for treatment of chronic pain: the patient perspective. Pain Med 6:336–345. https://doi.org/10.1111/j.1526-4637.2005.00059.x CrossRefPubMed

13.

Yi TI, Kim BK, Ha SA, Lim JY (2014) The relationships between determination of treatment success and emotional factors in patients with chronic musculoskeletal pain. Ann Rehabil Med 38:77–83. https://doi.org/10.5535/arm.2014.38.1.77 CrossRefPubMedPubMedCentral

14.

Zeppieri G, Lentz TA, Atchison JW et al (2012) Preliminary results of patient-defined success criteria for individuals with musculoskeletal pain in outpatient physical therapy settings. Arch Phys Med Rehabil 93:434–440. https://doi.org/10.1016/j.apmr.2011.10.007 CrossRefPubMed

15.

Howlader N, Noone A, Krapcho M, et al (2017) SEER cancer statistics review, 1975-2014. http://seer.cancer.gov/csr/1975_2014/. Accessed 12 December 2017

16.

Sundquist M, Brudin L, Tejler G (2017) Improved survival in metastatic breast cancer 1985–2016. Breast 31:46–50. https://doi.org/10.1016/j.breast.2016.10.005 CrossRefPubMed

17.

Hamer J, McDonald R, Zhang L, Verma S, Leahey A, Ecclestone C, Bedard G, Pulenzas N, Bhatia A, Chow R, DeAngelis C, Ellis J, Rakovitch E, Lee J, Chow E (2017) Quality of life (QOL) and symptom burden (SB) in patients with breast cancer. Support Care Cancer 25:409–419. https://doi.org/10.1007/s00520-016-3417-6 CrossRefPubMed

18.

Lloyd A, Nafees B, Narewska J, Dewilde S, Watkins J (2006) Health state utilities for metastatic breast cancer. Br J Cancer 95:683–690. https://doi.org/10.1038/sj.bjc.6603326 CrossRefPubMedPubMedCentral

19.

Callahan CM, Unverzagt FW, Hui SL, Perkins AJ, Hendrie HC (2002) Six-item screener to identify cognitive impairment among potential subjects for clinical research. Med Care 40:771–781. https://doi.org/10.1097/01.MLR.0000024610.33213.C8 CrossRefPubMed

20.

Kroenke K, Theobald D, Norton K, Sanders R, Schlundt S, McCalley S, Harvey P, Iseminger K, Morrison G, Carpenter JS, Stubbs D, Jacks R, Carney-Doebbeling C, Wu J, Tu W (2009) The Indiana Cancer Pain and Depression (INCPAD) trial: design of a telecare management intervention for cancer-related symptoms and baseline characteristics of study participants. Gen Hosp Psychiatry 31:240–253. https://doi.org/10.1016/j.genhosppsych.2009.01.007 CrossRefPubMedPubMedCentral

21.

Carpenter JS, Andrykowski MA, Cordova M, Cunningham L, Studts J, McGrath P, Kenady D, Sloan D, Munn R (1998) Hot flashes in postmenopausal women treated for breast carcinoma. Cancer 82:1682–1691. https://doi.org/10.1002/(SICI)1097-0142(19980501)82:9<1682::AID-CNCR14>3.0.CO;2-0 CrossRefPubMed

22.

Given B, Given CW, Sikorskii A, Jeon S, McCorkle R, Champion V, Decker D (2008) Establishing mild, moderate, and severe scores for cancer-related symptoms: how consistent and clinically meaningful are interference-based severity cut-points? J Pain Symptom Manag 35:126–135. https://doi.org/10.1016/j.jpainsymman.2007.03.012 CrossRef

23.

Gosain R, Miller K (2013) Symptoms and symptom management in long-term cancer survivors. Cancer J 19:405–409. https://doi.org/10.1097/01.PPO.0000434391.11187.c3 CrossRefPubMed

24.

Ozaslan C, Kuru B (2004) Lymphedema after treatment of breast cancer. Am J Surg 187:69–72. https://doi.org/10.1016/j.amjsurg.2002.12.003 CrossRefPubMed

25.

Cella D, Riley W, Stone A, Rothrock N, Reeve B, Yount S, Amtmann D, Bode R, Buysse D, Choi S, Cook K, Devellis R, DeWalt D, Fries JF, Gershon R, Hahn EA, Lai JS, Pilkonis P, Revicki D, Rose M, Weinfurt K, Hays R, PROMIS Cooperative Group (2010) The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008. J Clin Epidemiol 63:1179–1194. https://doi.org/10.1016/j.jclinepi.2010.04.011 CrossRefPubMedPubMedCentral

26.

Portenoy RK, Thaler HT, Kornblith AB, McCarthy Lepore J, Friedlander-Klar H, Kiyasu E, Sobel K, Coyle N, Kemeny N, Norton L, Scher H (1994) The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 30:1326–1336. https://doi.org/10.1016/0959-8049(94)90182-1 CrossRef

27.

Hahn EA, DeWalt DA, Bode RK et al (2014) New English and Spanish social health measures will facilitate evaluating health determinants. Health Psychol 33:490–499. https://doi.org/10.1037/hea0000055 CrossRefPubMedPubMedCentral

28.

Dajczman E, Kasymjanova G, Kreisman H, Swinton N, Pepe C, Small D (2008) Should patient-rated performance status affect treatment decisions in advanced lung cancer? J Thorac Oncol 3:1133–1136. https://doi.org/10.1097/JTO.0b013e318186a27 CrossRefPubMed

29.

Hegel MT, Collins ED, Kearing S, Gillock KL, Moore CP, Ahles TA (2008) Sensitivity and specificity of the distress thermometer for depression in newly diagnosed breast cancer patients. Psychooncology 17:556–560. https://doi.org/10.1002/pon.1289 CrossRefPubMedPubMedCentral

30.

Cohen SR, Mount BM, Tomas JJ et al (1996) Existential well-being is an important determinant of quality of life: evidence from the McGill quality of life questionnaire. Cancer 77:576–586. https://doi.org/10.1002/(SICI)1097-0142(19960201)77:3<576::AID-CNCR22>3.0.CO;2-0 CrossRefPubMed

31.

Kline RB (2011) Principles and practice of structural equation modeling, 3rd edn. Guilford Press, New York

32.

O'Farrell E, Smith A, Collins B (2016) Objective-subjective disparity in cancer-related cognitive impairment: does the use of change measures help reconcile the difference? Psychooncology 26:1667–1674. https://doi.org/10.1002/pon.4190 CrossRefPubMed

33.

Parisi JM, Rebok GW, Xue QL, Fried LP, Seeman TE, Tanner EK, Gruenewald TL, Frick KD, Carlson MC (2012) The role of education and intellectual activity on cognition. J Aging Res 2012:1–9. https://doi.org/10.1155/2012/416132\CrossRef

34.

Smith TJ, Saiki CB (2015) Cancer pain management. Mayo Clin Proc 90:1428–1439. https://doi.org/10.1016/j.mayocp.2015.08.009 CrossRefPubMed

35.

Butt Z, Rosenbloom SK, Abernethy AP, Beaumont JL, Paul D, Hampton D, Jacobsen PB, Syrjala KL, von Roenn JH, Cella D (2008) Fatigue is the most important symptom for advanced cancer patients who have had chemotherapy. J Natl Compr Cancer Netw 6:448–455. https://doi.org/10.6004/jnccn.2008.0036 CrossRef

36.

Cella D, Rosenbloom SK, Beaumont JL, Yount SE, Paul D, Hampton D, Abernethy AP, Jacobsen PB, Syrjala K, von Roenn JH (2011) Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer. J Natl Compr Cancer Netw 9:268–278. https://doi.org/10.6004/jnccn.2011.0026 CrossRef

37.

Mosher CE, Daily S, Tometich D et al (2016) Factors underlying metastatic breast cancer patients’ perceptions of symptom importance: a qualitative analysis. Eur J Cancer Care 27:1–6. https://doi.org/10.1111/ecc.12540 CrossRef

38.

Deckx L, van Abbema DL, van den Akker M, van den Broeke C, van Driel M, Bulens P, Tjan-Heijnen VCG, Kenis C, de Jonge ET, Houben B, Buntinx F (2015) A cohort study on the evolution of psychosocial problems in older patients with breast or colorectal cancer: comparison with younger cancer patients and older primary care patients without cancer. BMC Geriatr 15:79–91. https://doi.org/10.1186/s12877-015-0071-7 CrossRefPubMedPubMedCentral

39.

Menning S, de Ruiter MB, Kieffer JM, Agelink van Rentergem J, Veltman DJ, Fruijtier A, Oldenburg HSA, Boven E, van der Meij S, Lustig V, Bos MEM, Boogerd W, Reneman L, Schagen SB (2016) Cognitive impairment in a subset of breast cancer patients after systemic therapy: results from a longitudinal study. J Pain Symptom Manag 52:560–569. https://doi.org/10.1016/j.jpainsymman.2016.04.012 CrossRef

40.

Kwekkeboom KL (2016) Cancer symptom cluster management. Semin Oncol Nurs 32:373–382. https://doi.org/10.1016/j.soncn.2016.08.004 CrossRefPubMedPubMedCentral

41.

Starkweather AR, Lyon DE, Elswick RJ, Montpetit A, Conley Y, McCain N (2013) A conceptual model of psychoneurological symptom cluster variation in women with breast cancer: bringing nursing research to personalized medicine. Curr Pharmacogenom Person Med 11:224–230. https://doi.org/10.2174/18756921113119990004 CrossRef

42.

Garland SN, Johnson JA, Savard J, Gehrman P, Perlis M, Carlson L, Campbell T (2014) Sleeping well with cancer: a systematic review of cognitive behavioral therapy for insomnia in cancer patients. Neuropsychiatr Dis Treat 10:1113–1124. https://doi.org/10.2147/NDT.S47790 CrossRefPubMedPubMedCentral

43.

Carroll JK, Kohli S, Mustian KM, Roscoe JA, Morrow GR (2007) Pharmacologic treatment of cancer-related fatigue. Oncologist 12:43–51. https://doi.org/10.1634/theoncologist.12-S1-43 CrossRefPubMed

Titel: Metastatic breast cancer patients’ expectations and priorities for symptom improvement
verfasst von: Danielle B. Tometich
Catherine E. Mosher
Adam T. Hirsh
Kevin L. Rand
Shelley A. Johns
Marianne S. Matthias
Samantha D. Outcalt
Bryan P. Schneider
Lida Mina
Anna Maria V. Storniolo
Erin V. Newton
Kathy D. Miller
Publikationsdatum: 07.05.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 11/2018
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-018-4244-8

Predictive value of PCT and IL-6 for bacterial infection in children with cancer and febrile neutropenia

Open Access
Original Article

Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial

Original Article

Knowledge, attitudes, and practice of oncologists and oncology health care providers in promoting physical activity to cancer survivors: an international survey

Original Article

Neuropsychological profiles of breast cancer and brain tumor cohorts in Northeast Ontario, Canada

Original Article

Impact of radiation-induced nausea and vomiting on quality of life

Original Article

Portraying a grim illness: lung cancer in novels, poems, films, music, and paintings

Open Access
Original Article

Neu im Fachgebiet Onkologie

Adjuvanter PD-L1-Hemmer verhindert Rezidive bei Hochrisiko-Urothelkarzinom

15.01.2025
Urothelkarzinom
Nachrichten

Sind Menschen mit muskelinvasivem Urothelkarzinom für die neoadjuvante platinbasierte Therapie nicht geeignet oder sprechen sie darauf nicht gut an, ist Pembrolizumab eine adjuvante Alternative: Die krankheitsfreie Lebenszeit wird dadurch mehr als verdoppelt.

Duale Checkpointhemmung gegen Melanome verlängert langfristig das Leben

15.01.2025
Melanom
Nachrichten

Im Vergleich zu den Überlebenschancen vor der Einführung von Immuncheckpointhemmern (ICI) ist der Fortschritt durch eine ICI-Kombination mit unterschiedlichen Tagets bei fortgeschrittenem Melanom erstaunlich. Das belegen die finalen Ergebnisse der CheckMate-067-Studie und geben Betroffenen "Hoffnung auf Heilung".

Knochenmarktransplantat als Chance für ältere AML-Patienten

15.01.2025
Akute myeloische Leukämie
Nachrichten

Lange Zeit ist die Transplantation von hämatopoetischen Stammzellen nur bei jüngeren Patienten mit akuter myeloischer Leukämie praktiziert worden. Inzwischen profitieren auch Ältere davon. Ergebnisse einer Studie unterstützen dieses Vorgehen.

Nierenzellkarzinom: Kein Nachteil durch subkutan appliziertes Nivolumab

14.01.2025
Nierenkarzinom
Nachrichten

Die subkutane Applikation von Nivolumab ist nach Daten einer Phase-3-Studie ähnlich gut wirksam wie die intravenöse: Die Pharmakokinetik ist vergleichbar, die objektive Response war in der Studie sogar leicht besser als in der Gruppe mit Infusionen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Metastatic breast cancer patients’ expectations and priorities for symptom improvement